Satsuma Pharmaceuticals

OverviewSuggest Edit

Satsuma Pharmaceuticals is focused on developing best-in-class products to address the unmet needs of migraine sufferers.

TypePublic
Founded2016
HQSouth San Francisco, US
Websitesatsumarx.com

Latest Updates

Employees (est.) (Jun 2019)11
Share Price (Feb 2020)$29.4 (+5%)

Satsuma Pharmaceuticals Office Locations

Satsuma Pharmaceuticals has offices in South San Francisco and Durham
South San Francisco, US (HQ)
400 Oyster Point Blvd #221South
Durham, US
4819 Emperor Blvd #340
Show all (2)

Satsuma Pharmaceuticals Financials and Metrics

Satsuma Pharmaceuticals Revenue

USD

Net income (Q3, 2019)

(8.3m)

EBIT (Q3, 2019)

(8.5m)

Market capitalization (13-Feb-2020)

510.0m

Closing stock price (13-Feb-2020)

29.4

Cash (30-Sept-2019)

77.7m

EV

437.4m
Satsuma Pharmaceuticals's current market capitalization is $510 m.
Annual
USDFY, 2017FY, 2018

General and administrative expense

754.0k1.1m

R&D expense

4.2m6.4m

Operating expense total

4.9m7.5m

EBIT

(4.9m)(7.5m)
Quarterly
USDQ3, 2019

General and administrative expense

1.0m

R&D expense

7.4m

Operating expense total

8.5m

EBIT

(8.5m)
Annual
USDFY, 2017FY, 2018

Cash

1.7m5.2m

Prepaid Expenses

256.0k199.0k

Current Assets

1.9m5.4m

PP&E

70.0k445.0k
Quarterly
USDQ3, 2019

Cash

77.7m

Prepaid Expenses

7.6m

Current Assets

126.6m

PP&E

885.0k
Annual
USDFY, 2017FY, 2018

Net Income

(5.2m)(7.3m)

Depreciation and Amortization

10.0k57.0k

Accounts Payable

363.0k(177.0k)

Cash From Operating Activities

(4.3m)(7.0m)
Quarterly
USDQ3, 2019

Net Income

(17.4m)

Depreciation and Amortization

102.0k

Accounts Payable

1.4m

Cash From Operating Activities

(22.4m)
USDY, 2019

EV/EBIT

-51.6 x

EV/CFO

-19.5 x

Financial Leverage

1.1 x
Show all financial metrics

Satsuma Pharmaceuticals Operating Metrics

Aug, 2019

Drugs in Development

37

Patents (Foreign)

9

Patents (US)

6
Show all operating metrics

Satsuma Pharmaceuticals Online and Social Media Presence

Embed Graph

Satsuma Pharmaceuticals News and Updates

Satsuma Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Sept. 12, 2019 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc. ("Satsuma" or the "Company") (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced...

Satsuma Pharmaceuticals sets IPO terms to raise up to $80 million

Satsuma Pharmaceuticals Inc. has set terms for its initial public offering, to raise up to $80 million and value the biopharmaceutical company, which is developing migraine treatments, at about $257.7 million. San Francisco-based Satsuma is offering 5 million shares in the IPO, which is expected to…

Satsuma Pharmaceuticals Appoints Elisabeth Sandoval to Board of Directors

SOUTH SAN FRANCISCO, Calif., May 29, 2019 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc. ("Satsuma" or "the Company"), a Phase 3-stage biopharmaceutical company developing STS101, (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced that Elisabeth...

Satsuma Pharmaceuticals Provides Corporate Update and Prepares to Advance Lead Product Candidate, STS101, Into Phase 3 Efficacy Trial for Acute Migraine

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc. ("Satsuma" or "the Company"), a clinical-stage biopharmaceutical company, today provided a corporate update, including recent progress with its development of STS101 for the acute treatment of...

Satsuma Pharmaceuticals Blogs

Analytical Manager

Location: RTP North Carolina Satsuma Pharmaceuticals: Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic for the acute treatment of migraine.  Our lead drug candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of di…

Satsuma Pharmaceuticals Frequently Asked Questions

  • When was Satsuma Pharmaceuticals founded?

    Satsuma Pharmaceuticals was founded in 2016.

  • How many employees does Satsuma Pharmaceuticals have?

    Satsuma Pharmaceuticals has 11 employees.

  • Who are Satsuma Pharmaceuticals competitors?

    Competitors of Satsuma Pharmaceuticals include Horizon Therapeutics, Esperion Therapeutics and Mylan.

  • Where is Satsuma Pharmaceuticals headquarters?

    Satsuma Pharmaceuticals headquarters is located at 400 Oyster Point Blvd #221South, South San Francisco.

  • Where are Satsuma Pharmaceuticals offices?

    Satsuma Pharmaceuticals has offices in South San Francisco and Durham.

  • How many offices does Satsuma Pharmaceuticals have?

    Satsuma Pharmaceuticals has 2 offices.